{"id":326,"date":"2021-01-24T15:48:46","date_gmt":"2021-01-24T14:48:46","guid":{"rendered":"https:\/\/kaczmarski-legal.com.pl\/?page_id=326"},"modified":"2025-03-13T08:39:15","modified_gmt":"2025-03-13T07:39:15","slug":"about-me","status":"publish","type":"page","link":"https:\/\/kaczmarski-legal.com.pl\/?page_id=326&lang=en","title":{"rendered":"About me"},"content":{"rendered":"\n
<\/div>\n\n\n\n
\n\n\n\n
\"\"<\/figure>
\n

I am a graduate of the Faculty of Law and Administration of the University of Warsaw (master’s thesis, 2001<\/strong>; PhD, 2014<\/strong>), specialising in financial crime, white-collar defense and forensic sciences<\/strong>. From 2016<\/strong> I am also an advocate<\/strong> and a member of the Warsaw Bar Association.<\/p>\n<\/div><\/div>\n\n\n\n

<\/div>\n\n\n\n

In the years 2003 – 2012<\/strong>, I gained experience as an investigative auditor (forensic investigator) while working for Deloitte, EY and KPMG. During this stage of my professional career, I had the opportunity to deal with:<\/p>\n\n\n\n

    \n
  • investigations into allegations of corruption<\/strong> related to violations of the US anti-corruption law FCPA<\/strong>; projects took place in the region of Central and Eastern Europe, Germany, Switzerland, Austria, Great Britain, USA and India,<\/li>\n\n\n\n
  • corporate internal investigations<\/strong> into allegations of violation of internal procedures or laws in companies representing the financial, pharmaceutical, fuel, telecommunications and many other industries (allegations included inter alia instances of mobbing, conflict of interest, abuse of powers or failure to fulfill obligations leading to damage to the company, criminal threats, embezzlement of assets, fraud),<\/li>\n\n\n\n
  • compliance reviews<\/strong> in companies from the financial sector (AML, economic and anti-terrorist sanctions), pharmaceutical sector (anti-corruption, conflict of interest management, AML, acts of unfair competition) and many more,<\/li>\n\n\n\n
  • substantive and technical support in ongoing court disputes<\/strong> (identifying and securing evidence in the case, building a defense or attack strategy, estimating the value of the subject matter of the dispute or the value of damage, participating in the preparation of legal opinions or acting as expert witness)<\/li>\n\n\n\n
  • conducting training<\/strong> in the areas indicated above.<\/li>\n<\/ul>\n\n\n\n

    In the years 2012 \u2013 2017<\/strong>, I served as a regional compliance manager at the pharmaceutical company Amgen (Poland, Lithuania, Latvia, Estonia). As part of this role, my tasks included:<\/p>\n\n\n\n

      \n
    • monitoring of compliance<\/strong> with internal procedures,<\/li>\n\n\n\n
    • compliance training<\/strong> for employees and monitoring the implementation of the training program,<\/li>\n\n\n\n
    • coordination of internal investigations<\/strong>, including the whistleblowing program,<\/li>\n\n\n\n
    • business support<\/strong> in dealing with dilemmas in achieving business goals,<\/li>\n\n\n\n
    • substantive and logistical support<\/strong> as part of internal and external audits and reviews<\/strong>.<\/li>\n<\/ul>\n\n\n\n

      In the years 2017-2020<\/strong>, I served as the president of the management board (CEO) of the National Medicines Verification Organisation (KOWAL). Within my mandate I was responsible for:<\/p>\n\n\n\n

        \n
      • launching <\/strong>the European Medicines Verification System in Poland and its daily maintenance and administration<\/strong>,<\/li>\n\n\n\n
      • coordination of the connection with the system<\/strong> of national pharmaceutical wholesalers, community and hospital pharmacies, and the Chief Pharmaceutical Inspectorate (as the national competent authority supervising the System and its users, including KOWAL),<\/li>\n\n\n\n
      • coordination of the integration of the national system with the central hub<\/strong> of the European Medicines Verification System,<\/li>\n\n\n\n
      • execution by the KOWAL Foundation of tasks arising from the Delegated Regulation of the European Commission EU 2016\/161 <\/strong>of 2 October 2015 supplementing Directive 2001\/83\/EC of the European Parliament and of the Council by defining detailed rules regarding security features placed on the packaging of medicinal products for human use<\/li>\n<\/ul>\n\n\n\n

        From 2021<\/strong>, as a legal attorney (advocate)<\/strong>, I support clients in developing and implementing preventive and defense strategies<\/strong> in the event of alleged crime or violations of compliance rules<\/strong>.<\/p>\n\n\n\n

        <\/div>\n\n\n\n

        <\/p>\n\n\n\n